Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2405
Peer-review started: January 2, 2023
First decision: January 20, 2023
Revised: February 2, 2023
Accepted: March 17, 2023
Article in press: March 17, 2023
Published online: April 16, 2023
Processing time: 94 Days and 9.4 Hours
Translational therapy refers to a combination of chemotherapy, radiotherapy, targeted therapy, and immunotherapy for patients with advanced gastric cancer who are initially unable to undergo R0 resection. This treatment can achieve partial or complete remission of the unresectable tumors to meet the criteria for R0 resection, thus enabling the patients to prolong their survival time and improve their quality of life. In gastric cancer, translational therapy has been tried and improved. At present, there are a large number of patients with locally advanced gastric cancer in China, and the selection of suitable patients for translational therapy to prolong objective survival and improve survival quality is one of the hot spots in the field of gastric cancer research.
Core Tip: In general, for patients with locally advanced gastric cancer, translational therapy can achieve different levels of survival benefit. Immunohistochemistry and genetic testing should be performed before treatment to select a more optimal comprehensive treatment strategy. For patients with locally advanced gastric cancer that is difficult to be resected at the initial stage, translational therapy followed by surgery can improve the survival benefit of patients.